59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.